What is Osmind, Inc.?
Founded in 2020 and headquartered in San Francisco, California, Osmind, Inc. is a pioneering organization in the mental health care space. The company is dedicated to advancing innovative treatments, with a particular focus on legal psychedelic medicine. This includes FDA-approved therapies such as ketamine and esketamine (Spravato), as well as treatments currently in clinical trials like MDMA and psilocybin. Osmind aims to integrate these novel therapeutic modalities into mainstream mental health care, addressing a critical need for effective and accessible treatments.
How much funding has Osmind, Inc. raised?
Osmind, Inc. has raised a total of $57M across 3 funding rounds:
Angel/Seed
$2M
Series A
$15M
Series B
$40M
Angel/Seed (2020): $2M with participation from General Catalyst Partners, What If Ventures, Jeffrey Leiden MD, and 20|20 Fund
Series A (2021): $15M led by Offline Ventures, AME Cloud Ventures, General Catalyst, Tiger Global, and Future Ventures
Series B (2022): $40M supported by DFJ Growth
Key Investors in Osmind, Inc.
General Catalyst Partners
General Catalyst is a venture capital firm that identifies and supports transformational business opportunities across multiple sectors and stages. They deploy capital strategically to back entrepreneurs pursuing ambitious visions that reshape industries, leveraging deep sector expertise and operational experience to accelerate growth and build enduring enterprises.
AME Cloud Ventures
AME Cloud Ventures is a venture fund led by Jerry Yang, co-founder of Yahoo!, focusing on seed to later-stage companies that build infrastructure and value chains around data. The firm invests in technology-heavy companies that gather or create unique data across various stages of the data stack.
DFJ Growth
DFJ Growth is a late-stage global venture capital firm providing capital to companies in seed, early, and growth-stages. They invest in rapidly scaling technology companies poised for market leadership.
What's next for Osmind, Inc.?
The recent major strategic investment positions Osmind, Inc. for accelerated scaling and further development of its innovative mental health care platform. With a clear focus on legal psychedelic medicine and a commitment to expanding treatment accessibility, the company is poised to capture a significant share of a rapidly evolving market. Future endeavors will likely involve expanding clinical partnerships, enhancing technological infrastructure, and potentially exploring further funding rounds to support broader market penetration and research initiatives.
See full Osmind, Inc. company page
